UFIS-SWE-IG
0.1.0 - ci-build

UFIS-SWE-IG, published by UNICOM. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/ufis-swe-ig/ and changes regularly. See the Directory of published versions

: Oxascand-5mg-Tablet-SE-IS-APD - XML Representation

Raw xml | Download



<AdministrableProductDefinition xmlns="http://hl7.org/fhir">
  <id value="Oxascand-5mg-Tablet-SE-IS-APD"/>
  <meta>
    <profile
             value="http://unicom-project.eu/fhir/StructureDefinition/PPLAdministrableProductDefinition"/>
  </meta>
  <text>
    <status value="generated"/>
    <div xmlns="http://www.w3.org/1999/xhtml"><p class="res-header-id"><b>Generated Narrative: AdministrableProductDefinition Oxascand-5mg-Tablet-SE-IS-APD</b></p><a name="Oxascand-5mg-Tablet-SE-IS-APD"> </a><a name="hcOxascand-5mg-Tablet-SE-IS-APD"> </a><a name="hcOxascand-5mg-Tablet-SE-IS-APD-en-US"> </a><p><b>status</b>: Active</p><p><b>formOf</b>: <a href="MedicinalProductDefinition-Oxascand-5mg-Tablet-SE-IS-MPD.html">MedicinalProductDefinition: identifier = http://ema.europa.eu/fhir/mpId#SE-100001594-00011082,http://ema.europa.eu/fhir/eurdId#2234; domain = Human use; status = Current; combinedPharmaceuticalDoseForm = Tablet; indication = Oxascand påverkar de vid ångestsyndrom vanliga symtomen: ängslan, ångest, rastlöshet och  sömnsvårigheter. Vid depressioner med inslag av nyss nämnda symtom kan Oxascand användas  tillsammans med sedvanliga antidepressiva farmaka. Delirium tremens, predeliriösa tillstånd och akuta abstinenssymtom som ångest, spänning och  excitation i samband med alkoholmissbruk.; legalStatusOfSupply = Medicinal product subject to special medical prescription; classification = N05BA04</a></p><p><b>administrableDoseForm</b>: <span title="Codes:{https://spor.ema.europa.eu/v1/lists/200000000004 100000073664}">Tablet</span></p><p><b>producedFrom</b>: <a href="ManufacturedItemDefinition-Oxascand-5mg-Tablet-SE-IS-MID.html">ManufacturedItemDefinition: status = active; manufacturedDoseForm = Tablet; unitOfPresentation = Tablet</a></p><h3>RouteOfAdministrations</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Code</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{https://spor.ema.europa.eu/v1/lists/100000073345 100000073619}">Oral use</span></td></tr></table></div>
  </text>
  <status value="active"/>
  <formOf>🔗 
    <reference
               value="MedicinalProductDefinition/Oxascand-5mg-Tablet-SE-IS-MPD"/>
  </formOf>
  <administrableDoseForm>
    <coding>
      <system value="https://spor.ema.europa.eu/v1/lists/200000000004"/>
      <code value="100000073664"/>
      <display value="Tablet"/>
    </coding>
  </administrableDoseForm>
  <producedFrom>🔗 
    <reference
               value="ManufacturedItemDefinition/Oxascand-5mg-Tablet-SE-IS-MID"/>
  </producedFrom>
  <routeOfAdministration>
    <code>
      <coding>
        <system value="https://spor.ema.europa.eu/v1/lists/100000073345"/>
        <code value="100000073619"/>
        <display value="Oral use"/>
      </coding>
    </code>
  </routeOfAdministration>
</AdministrableProductDefinition>